24/7 Market News Snapshot 10 March, 2025 – Trevi Therapeutics, Inc. Common Stock (NASDAQ:TRVI)

March 10, 2025

DENVER, Colo., 10 March, 2025 (247marketnews.com) – (NASDAQ:TRVI) are discussed in this article.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) is currently experiencing a significant surge in trading as it marks a substantial 23.56% increase, reaching $5.31 in pre-market activity, up from the previous close of $4.30. This notable uptick is accompanied by a trading volume of 1.39 million shares, reflecting heightened investor enthusiasm and strong market interest. Analysts are observing key technical indicators that suggest further bullish momentum could be on the horizon.

This surge follows the company’s recent announcement regarding promising topline results from its Phase 2a RIVER trial of Haduvio™ (oral nalbuphine ER), designed to address refractory chronic cough (RCC). The trial, which involved 66 participants, revealed a statistically significant 57% reduction in 24-hour cough frequency, exceeding expectations with a p-value of less than 0.0001. These outcomes not only achieved the study’s primary endpoint but also demonstrated effectiveness across both moderate and severe cough subgroups. Remarkably, Haduvio stands out as the first therapy to show significant improvements in chronic cough associated with both RCC and idiopathic pulmonary fibrosis (IPF).

Jennifer Good, President and CEO of Trevi Therapeutics, highlighted the company’s commitment to addressing a longstanding therapeutic gap, stating that these results affirm Haduvio’s potential to transform patient care in chronic cough, a condition with historically limited treatment options. Chief Development Officer James Cassella emphasized the urgency for effective therapies for the nearly 84% of patients treated with Haduvio who reported at least a 30% decrease in cough frequency, compared to just 29% in the placebo group.

With the enthusiasm from both the market and positive clinical trial results, Trevi Therapeutics plans to engage with regulatory authorities to discuss the next steps for Haduvio’s development, aiming to bring this innovative therapy to patients in need.

Related news for (TRVI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.